1 / 29

Vasodilates

Vasodilates. Michael Evans April 17, 2008. Overview. History Purposes of vasodilates Mechanisms of different vasodilates Commonly used vasodilators, for therapeutic effects. History.

bernad
Download Presentation

Vasodilates

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Vasodilates Michael Evans April 17, 2008

  2. Overview • History • Purposes of vasodilates • Mechanisms of different vasodilates • Commonly used vasodilators, for therapeutic effects

  3. History • Nobel Prize in Medicine awarded in 1998 to 3 physicians "for their discoveries concerning nitric oxide as a signalling molecule in the cardiovascular system"

  4. History, continued • Synthesized in 1846, nitroglycerin was first used to treat anginal attacks in 1879. It was granted FDA approval in 1938. • Explosion of vasodilator therapy research in the 1970’s • When ACE inhibitor therapy first appeared • More research in the 80’s and 90’s to determine long-term effects, as usage to garner acute effects has already been proven to work • One can build up a tolerance to vasodilators, so dosages must be increased or there must be a nitrate-free interval • Since all methods work via different mechanisms and pathways, there’s no such thing as simple “vasodilator research” • Nitroprusside • Nitrates • ACE inhibitors • Angiotensin II antagonists • Calcium Channel Blockers • Nitroprusside, nitrates, hydralazine are direct vasodilators • AII antagonists and ACE inhibitors also have indirect components

  5. History, continued • VHeFTI trial (1986) – first to prove increased survival rates with vasodilator treatment [for patients with Class II and Class III heart failure] • Known as a mortality study • Vasodilation affects the relationship between mean arterial pressure, cardiac output, and total peripheral resistance • Your heart pumps against a constant pressure, and you can damage your heart if TPR is too high [hypertension/high blood pressure] • Although blood viscosity [hematocrit-determined] and length of blood vessels contribute to TPR, the most important variable is vessel diameter, which relates directly to surrounding smooth muscle

  6. Blood Vessels

  7. Homeostatic Mechanisms • Baroreceptors • Constant monitor • Neck/chest most important • When there is a change in blood pressure, physiologic mechanisms triggered

  8. Extreme Dilation of Blood Vessels • Alcohol • Some allergic reactions • Some antidepressants • amitriptyline • Antihypertensive drugs that dilate blood vessels (such as calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers) • Nitrates • Bacterial infections • Heat • Nerve damage (such as that due to diabetes, amyloidosis, or spinal cord injuries) • In this case, the homeostatic controls lose their function

  9. Endogenous [rising from within] Vasodilators • Depolarization, which yields decreased intracellular Ca2+ • Nitric Oxide Pathway, stimulating cGMP  MLCK pathway, which ends up decreasing intracellular Ca2+ • Beta-2 Andrenergic Receptor antagonists, histamine, prostaglandins, and prostacyclin • VIP • Adenosine • ATP and ADP • L-Arginine • Bradykinin • Muscle use

  10. Endogenous Vasodilators: Hyperpolarization • Endothelium-derived hyperpolarizing factor [EDHF] • Depolarization, which opens Voltage-gated K+ channels • Increase in Interstitial K+ • All of the above hyperpolarize the membrane, closing voltage-dependent calcium channels, decreasing intracellular Ca2+ • Effectively the same as Ca2+ channel blockers

  11. Hyperpolarization: Intracellular Ca2+ • As you know, muscle contraction occurs when VDCC’s open, allowing Ca2+ to flow into the cell • A vasodilator needs to inhibit smooth muscle contraction [around blood vessels] • Thus, membrane hyperpolarization to prevent these voltage gated channels from opening works to achieve this goal

  12. Endogenous Vasodilators: Nitric Oxide • Nitric Oxide acts on the lyase enzyme Guanylate Cyclase [GC] • This enzyme catalyzes the conversion of GTP to 3’,5’-cyclic guanosine monophosphate [better known as cGMP] and pyrophosphate • Because there are multiple GC’s, one membrane-bound and one soluble, it is important to clarify that the NO-receptor is the soluble GC receptor • cGMP then regulates cellular proteins, yielding vasodilation GTP cGMP

  13. cGMP Mechanisms of Action • Second messenger • Activates intracellular protein kinases [pk’s] • cGMP relaxes smooth muscles

  14. Renin-Angiotensin-Aldosterone Systemas it pertains to vasodilation • RAA system is blocked with ACEI • Angiotensin II is turned off • This allows indirect acute vasodilatation through withdrawal of angiotensin II and the accumulation of bradykinin (as ACEI are kininases) which also contributes to the vasodilator effect

  15. Bradykinin • 9-AA Peptide Chain • Released from Venules • Endothelium-dependent vasodilator • Broken down by Angiotensin-converting enzyme (ACE)

  16. Exogenous [from outside the body] Vasodilators • Quiet, dark • Adenosine antagonists • Alpha-blockers • Amyl nitrite - popper • Alcohol [ethanol] • Histamine-inducers • Nitric Oxide Inducers • THC

  17. Environmental Factors • Noise • Excessive noise, annoying noise • Raise blood pressure, cause hypertension • Increased stress shown by study • 5-10 point rise in blood pressure, vasoconstriction • Light • Clinically measurable stress found from overexposure • People that work in extremely bright environments are more prone to hypertension

  18. Calcium Channel Blockers • Calcium channel blockers reduce heart rate • Dilate the blood vessels of the heart • Decrease oxygen demand • Increase oxygen supply • Net drop in BP

  19. Alpha-Blockers • Alpha-adrenergic blocking agents • In both arteries and smooth muscles • The blocked adrenergic receptors are G protein-coupled receptors • Catecholamines – adrenaline/noradrenaline[epi/norepi] • If catecholamines bind, increased HR, vasoconstriction • However, if B-adrenergic receptors are bound by epi or norepi, vasodilation occurs

  20. More on Alpha Adrenergic Receptors

  21. Nitric Oxide [NO] Inducers • Glyceryl trinitrate (Nitroglycerin) • Prodrug, must be denitrated to produce active NO • Once active, these nitrates are called “nitrovasodilators”

  22. Mechanisms for Denitration • Nitroglycerin can be denitrated in many ways • There are many hypotheses as to the mechanism of bioactivation • Nitrates react with sulfhydryl groups • Enzymatic breakdown • Glutathione S-transferase, Cytochrome P450, Xanthine oxidoreductase • Catalyzed denitration by mitochondrial aldehyde dehydrogenase • Ultimately, GTN is broken down into 1,2-glyceryl dinitrate + Free NO

  23. Other Nitric Oxide [NO] Inducers • Isosorbide mononitrate & Isosorbide dinitrate • Preventatives of angina, reduced heart workload • Pentaerythritol Tetranitrate (PETN) • Lentonitrat – drug commonly used, pure PETN • So reactive…one of the strongest high explosives known • Sodium nitroprusside • Salt that is a source of NO, often administered via IV • For patients with extreme hypertension • PDE5 inhibitors: these agents indirectly increase the effects of nitric oxide • Sildenafil (Viagra) • Tadalafil • Vardenafil

  24. Now what? Free NO • NO is a potent activator of guanylyl cyclase (GC) by heme-dependent mechanisms • Activation results in cGMP formation from guanosine triphosphate (GTP) • Thus, NO increases the level of cGMP within the cell.

  25. Nitroglycerin • GENERIC NAME: nitroglycerin • BRAND NAME: Nitro-Bid; Nitro-Dur; Nitrostat; Transderm-Nitro; Minitran; Deponit; Nitrol • USES: frequently used to lower blood pressure when treating angina pectoris, and also used during anginal attacks [both as a prevention method, and as an acute treatment] • Extended release tablets, translingual spray, and transdermal patches • Literature recommends not to stack with other high blood pressure medications, because of additive effects

  26. ACE inhibitors • Class of Drugs: ACE (angiotensin converting enzyme) inhibitors • Generic (Brand Name) • captopril (Capoten) • benazepril (Lotensin) • enalapril (Vasotec) • lisinopril (Prinivil, Zestril) • fosinopril (Monopril) • ramipril (Altace) • perindopril (Aceon) • quinapril (Accupril) • moexipril (Univasc) • trandolapril (Mavik) • USES: • Hypertension treatment • Heart failure

  27. Viagra (sildenafil citrate) • More than 65% of men with high blood pressure also have ED. • PDE5 Inhibitor • Side Effects • Priaprism • Sudden blindness

  28. OTC Vasodilates • Preworkout supplements • Taken 30 minutes before exercise • Stimulate L-Arginine pathway, along with NOS

  29. Sources • http://nobelprize.org/nobel_prizes/medicine/laureates/1998/index.html • http://en.wikipedia.org/wiki/Nitric_oxide • http://www.medicinenet.com/nitroglycerin/article.htm • http://www.medicinenet.com/ace_inhibitors/article.htm • http://www.seloken.com/3430_9816.aspx?l1=&l2=&mid= • ^ S. Rosen and P. Olin, Hearing Loss and Coronary Heart Disease, Archives of Otolaryngology, 82:236 (1965) • http://en.wikipedia.org/wiki/Environmental_noise#cite_note-7 • http://en.wikipedia.org/wiki/Adrenergic_receptor#Alpha_.CE.B1_receptors • http://health.nytimes.com/health/guides/disease/coronary-heart-disease/other-medications.html • http://www.merck.com/mmhe/print/sec03/ch023/ch023a.html • http://en.wikipedia.org/wiki/Bradykinin • http://content.answers.com/main/content/wp/en-commons/thumb/4/47/220px-Nitroglycerin-2D-skeletal.png • http://en.wikipedia.org/wiki/Amitriptyline • http://wwwchem.csustan.edu/chem4400/SJBR/Image1.gif • http://fig.cox.miami.edu/~cmallery/150/memb/fig11x12.jpg • http://www.usm.maine.edu/~newton/Chy251_253/Lectures/BiopolymersIII/BradykininPrimary.gif • http://www.mc.uky.edu/pharmacology/images/ped_fin2.gif • http://en.wikipedia.org/wiki/PDE5_inhibitor

More Related